Javier Sosa, MD
Family Medicine · Fort Myers, FLNPI 1194816041
Payments from drug & device makers
Across 168 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$824
- GSK$522
- Novo Nordisk$420
- AbbVie$273
- Amgen$205
- Boston Scientific$186
- plus $925 from 20 others
What the payments were for
- Food & beverage$3,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $824 |
| GSK | 29 | $522 |
| Novo Nordisk | 19 | $420 |
| AbbVie(2 entities) | 15 | $273 |
| Amgen(2 entities) | 11 | $205 |
| Boston Scientific | 2 | $186 |
| Lilly USA, LLC | 7 | $127 |
| Merck | 5 | $100 |
| Dexcom, Inc. | 5 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| Pfizer | 4 | $84 |
| Spinefrontier, Inc. | 1 | $73 |
| Abbott | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| EMD Serono, Inc. | 2 | $32 |
| Exact Sciences | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Novartis | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$143
How this compares
$3,355 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $76,699 |
| OzempicSemaglutide | 55 | $62,029 |
| JardianceEmpagliflozin | 41 | $60,564 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $46,764 |
| TrulicityDulaglutide | 36 | $43,797 |
| JanuviaSitagliptin Phosphate | 35 | $38,921 |
| FarxigaDapagliflozin Propanediol | 24 | $33,733 |
| XareltoRivaroxaban | 14 | $24,273 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $22,941 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,938 |
| EntrestoSacubitril/Valsartan | 11 | $6,259 |
| Atrovent HfaIpratropium Bromide | 12 | $6,208 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,011 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,781 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $4,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $76,69968 claims |
| Novo NordiskOzempic | $420 | $62,02955 claims |
| MerckJanuvia, Janumet | $100 | $61,86249 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $522 | $61,71395 claims |
| Boehringer IngelheimJardiance | $21 | $60,56441 claims |
| Lilly USA, LLCTrulicity | $127 | $43,79736 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $824 | $42,71947 claims |
| NovartisEntresto | $19 | $6,25911 claims |
| AbbVieSynthroid | $273 | $1,38524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Myers
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.